A new study has helped to find out why Covid-19 can lead to abnormal blood clots, an unpleasant feature of the disease that can cause purple rash and swelling of the limbs, as well as an increased risk. muscle stroke and kidney failure.
Report in the magazine Medical translation scienceA team of researchers from the University of Michigan has come up with new evidence that the abnormal number of blood clots seen in Covid-19 patients is the result of white blood cells exploding and releasing autoantibodies. immunity induces blood clotting.
Called antiphospholipid autoantibodies, these clot-causing antibodies have been seen in patients with autoimmune disease antiphospholipid syndrome. They are produced by the immune system and target the individual̵7;s own cells, causing blood clots in the blood vessels.
It is clear that problematic autoimmune antibodies are also common in people hospitalized with Covid-19. Researchers found that about half of the patients who were seriously ill with Covid-19 had high levels of both autoantibodies and extracellular neutrophil trapping, which were the product of dangerous leukemia forms. dangerous and explosive. However, it is unclear what triggers the body to produce these antibodies.
“In patients with Covid-19, we continue to see a constant, self-amplifying, cycle of inflammation and coagulation in the body,” said Dr. Yogen Kanthi, co-author and assistant professor at Heart Center. Frankel Medical circuit Michigan, said in one declare. “Now we know that autoantibodies could be the culprit in this cycle of coagulation and inflammation, making already struggling people even sicker.”
To reinforce their hypothesis, the researchers introduced these exploding neutrophils and antibodies into mice and, as expected, noticed a significant amount of blood clotting.
“Antibodies from active Covid-19 infected patients have produced a significant amount of blood clotting in animals – one of the worst clotting phenomena we’ve ever seen,” Kanthi said. “We have discovered a new mechanism by which patients with Covid-19 can form blood clots.”
Blood clots are agar-like mass of cells and proteins that are the way the body stops bleeding. The prevalence of blood clots is not known in people infected with SARS-CoV-2, the coronavirus that causes Covid-19. However, the word studies Netherlands and France published earlier this year suggests that blood clots can arise in about 20 to 30 percent of seriously ill patients hospitalized with Covid-19. Another study in America showed have a blood clot in “almost every institution” that researchers reviewed.
Fortunately, researchers have some clues as to how to treat this unpleasant feature of Covid-19 and are pursuing new ways to prevent risky blood clots in patients. For example, researchers speculate that people at high risk of blood clots may be treated with plasma treatments, a treatment used in serious autoimmune diseases including: draw blood, filter and replace with fresh plasma. They are also embarking on a new randomized clinical trial to see if dipyridamole, an anticoagulant, is effective in reducing blood clots in Covid-19 patients.